For central monitoring of adult, pediatric, and neonatal patients; and where the clinician decides to monitor cardiac arrhythmia of adult, pediatric, and neonatal patients and/or ST segment of adult patients to gain information for treatment, to monitor adequacy of treatment, or to exclude causes of symptoms.

Device Description

The Philips Drug Calculator Software served by the Philips IntelliVue application server software (M2387A Application Server Software). The modification is primarily a software based change that incorporates the Rule of Six algorithm for IV drug computations in 100 mL IV bags.

AI/ML Overview

The provided text describes a 510(k) premarket notification for the Philips Drug Calculator Software. However, the documentation focuses primarily on the regulatory aspects of substantial equivalence and does not contain the specific details required to answer all questions about acceptance criteria and a dedicated study proving device performance against those criteria.

Here's what can be extracted and what information is missing:

1. A table of acceptance criteria and the reported device performance

The document does not explicitly list acceptance criteria or specific reported device performance in a quantitative manner. It states:

"Verification testing activities were conducted to establish the performance and reliability characteristics of the new device with respect to the predicate."
"Pass/Fail criteria were based on the specifications cleared for the predicate devices and test results showed substantial equivalence."

This indicates that internal specifications and the performance of predicate devices served as benchmarks, but the actual criteria and performance metrics are not detailed.

Missing Information for 2-9:

The provided text focuses on the 510(k) summary for the Philips Drug Calculator Software, emphasizing its substantial equivalence to previously cleared devices. It states that "Verification testing activities were conducted to establish the performance and reliability characteristics of the new device with respect to the predicate," and that "Pass/Fail criteria were based on the specifications cleared for the predicate devices and test results showed substantial equivalence."

However, the document does not provide the detailed information requested regarding sample sizes, data provenance, expert involvement, adjudication methods, details of comparative effectiveness studies (MRMC), standalone performance, types of ground truth, or training set specifics. The document is a regulatory submission summary, not a detailed study report.

Summary

{0}------------------------------------------------

K023674
RA12

NOV 2 9 2002

9.0 510 (k) Summary

This summary of 510(k) safety and effectiveness information is submitted in accordance with the requirements of the Safe Medical Devices Act of 1990 and 21 C.F.R. §807.92.

The submitter of this premarket notification is: David Osborn Philips Medical Systems Cardiac & Monitoring Systems 3000 Minuteman Road Andover, MA 01810-1099 978 659 3178 Tel: 978 685 5624 Fax: e-mail: d.g.osborn@ieee.org

This summary was prepared on October 30, 2002

1. The name of this device is the Philips Drug Calculator Software. Classification names are as follows:

Device Panel	Classification	ProCode	Description
Panel 74Cardiovascular	None	74 MHX	PhysiologicalMonitor, PatientMonitor
	870.1025, III	74 DSI	Arrhythmia Detectorand Alarm
	870.1025, III	74 MLD	Monitor, ST Alarm
	870.2800, II	74 DSH	Recorder, MagneticTape, Medical
	870.2300, II	74 MSX	System, Network andCommunication,PhysiologicalMonitors
Panel 73General & PlasticSurgery	868.1890, II	73 NDC	Calculator, DrugDose

1. The new device is substantially equivalent to previously cleared Philips devices marketed pursuant to K922058, K992636, and K021422.
1. The modification is primarily a software based change that incorporates the Rule of Six algorithm for IV drug computations in 100 mL IV bags.
1. The new device has the same intended use as the legally marketed predicate devices. They are used to display physiologic waves, parameters and, trends, to format data for compliant strip chart recorders, to format data for printed reports, and the secondary annunciation of alarms for multiple patients from other networked medical devices at a centralized location. To provide retrospective

{1}------------------------------------------------

review of alarms, physiologic waves and parameters. And to provide primary annunciation of alarms, and confiquration and control access for networked telemetry monitors at a centralized location.

1. The new device has the same technological characteristics as the legally marketed predicate devices.
1. Verification testing activities were conducted to establish the performance and reliability characteristics of the new device with respect to the predicate. Testing involved system level tests, integration tests, and safety testing from risk analysis. Pass/Fail criteria were based on the specifications cleared for the predicate devices and test results showed substantial equivalence.

{2}------------------------------------------------

DEPARTMENT OF HEALTH & HUMAN SERVICES

Image /page/2/Picture/1 description: The image contains the text 'Public Health Service'. The text is in a simple, sans-serif font and is left-aligned. The words are stacked on top of each other, with 'Public' on the top line, 'Health' on the second line, and 'Service' on the third line.

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

NOV 2 9 2002

Philips Medical Systems c/o Mr. Dave Osborn Quality Program Manager Cardiac and Monitoring Systems 3000 Minuteman Road Andover, MA 01810

Re: K023674

Trade Name: Philips Drug Calculator Software served by the Philips IntelliVue application server software (M2387A Application Server Software) Regulation Number: 21 CFR 870.1025

Regulation Name: Arrhythmia Detector and Alarm Regulatory Class: Class III (three) Product Code: MHX Dated: October 31, 2002 Received: November 1, 2002

Dear Mr. Osborn:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments. or 10 devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA). it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations. Title 21, Parts 800 to 898. In addition. FDA may publish further announcements concerning your device in the Federal Register.

{3}------------------------------------------------

Page 2 – Mr. Dave Osborn

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4646. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Elias Mallés

Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

Page -

510(k) Number (if known): ____________________________________________________________________________________________________________________________________________________

The Philips Drug Calculator Software served by the Device Name: Philips IntelliVue application server software (M2387A Application Server Software)

Indications for Use:

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

K0236 513(k) Number

Over-The-Counter Use Prescription Use X OR

(Per 21 CFR 801.109)

(Optional Format 1-2-96)

Regulation Number and Section

§ 870.1025 Arrhythmia detector and alarm (including ST-segment measurement and alarm).

(a)
Identification. The arrhythmia detector and alarm device monitors an electrocardiogram and is designed to produce a visible or audible signal or alarm when atrial or ventricular arrhythmia, such as premature contraction or ventricular fibrillation, occurs.(b)
Classification. Class II (special controls). The guidance document entitled “Class II Special Controls Guidance Document: Arrhythmia Detector and Alarm” will serve as the special control. See § 870.1 for the availability of this guidance document.